Illumina SEC filings document the company’s genomics technology business, financial results, governance and capital actions. Form 8-K reports cover quarterly and annual operating results, preliminary financial updates, share repurchase authorization, management and board changes, and Regulation FD disclosures.
The filing record also includes definitive proxy materials for annual meeting matters, director elections, compensation and shareholder voting. Material-event filings document completed acquisition activity, including the purchase of SomaLogic and Sengenics aptamer-based and functional proteomics assets, along with exhibits, common-stock repurchase disclosures and other capital-structure records.
Illumina, Inc. related funds reported sizable trading activity in the company’s common stock. Securities are held for the Corvex Funds, for which Corvex Management LP acts as investment adviser, and both Corvex and Keith Meister disclaim beneficial ownership beyond their pecuniary interests.
On May 13–14, 2026, the Corvex Funds conducted open-market sales totaling 329,460 shares of Illumina common stock at weighted average prices generally between about $144 and $148 per share, leaving 3,500,048 shares indirectly held after the last reported sale. Separately, on May 12, 2026, the funds exercised equity swaps representing 255,378 notional shares, with the counterparty paying $36,942,981.48 based on a market price of $144.66 per share, offset by $26,257,965.96 at a cost basis of $102.82 per notional share.
The partial termination of the equity swaps and the related purchases are described as exempt from Section 16(b) under Rule 16b-6(b). The remaining swaps, covering 24,562 notional shares at $102.82 per share, are scheduled to terminate on February 11, 2028 and will be settled in cash by default, with an option for physical settlement.
Illumina, Inc. filing shows Capital World Investors reports beneficial ownership of 15,776,452 shares, equal to 10.3% of 152,900,000 shares believed to be outstanding. The filing states CWI has sole voting power over 15,688,387 shares and sole dispositive power over 15,776,452 shares.
The Schedule 13G/A is labeled as an amendment and is signed by a Capital Research and Management Company officer. The disclosure describes the investment management structure and lists affiliated entities that comprise Capital World Investors.
Illumina, Inc. reported a notice of proposed sale of 600,000 shares of Common Stock under Form 144. The filing lists Common Stock, par value $0.01 per share and identifies Goldman Sachs & Co. LLC as the broker. The Form 144 record shows transactions dated 10/25/2023 and the filing date entry 05/13/2026.
The entry describes purchases of shares in the open market and lists cash as the consideration method. The notice names the Nasdaq Stock Market as the listing venue.
ILLUMINA, INC. director Keith A. Meister reported transactions tied to equity swaps held for the Corvex Funds. The funds partially terminated swaps referencing 9,236 and 79,568 notional Illumina shares, with the counterparty paying cash based on market prices above a cost basis of $102.82 per share.
In connection with these terminations, the Corvex Funds acquired common stock through in-the-money derivative exercises, with one line showing 79,568 shares at $102.82 and a resulting reported holding of 3,909,076 common shares after that transaction. The remaining swaps cover 279,940 notional shares at $102.82 per share and run to February 11, 2028, with cash settlement by default and an option for physical share settlement. Corvex and Mr. Meister disclaim beneficial ownership beyond their pecuniary interest.
ILLUMINA, INC. senior vice president Jakob Wedel Christensen reported routine transactions in the company’s common stock. On May 6, 2026, he executed an open-market sale of 700 shares at $139.04 per share. After this sale, he directly held 15,056 shares of Illumina common stock.
On May 5, 2026, a separate disposition of 233 shares at $139.07 per share was recorded as a tax-withholding transaction, meaning shares were surrendered to cover tax obligations rather than sold on the open market.
Illumina reported a solid first quarter of fiscal 2026 and increased its full-year outlook. Q1 2026 revenue was $1.09 billion, up 4.8% from Q1 2025, with GAAP operating margin improving to 19.2% and non-GAAP operating margin to 21.9%. GAAP diluted EPS rose to $0.87 from $0.82, while non-GAAP diluted EPS increased to $1.15 from $0.97.
Free cash flow was $251 million, up from $208 million, and cash flow from operations reached $289 million. For fiscal 2026, Illumina now guides to $4.52–$4.62 billion in revenue and non-GAAP EPS of $5.15–$5.30. The board also authorized a new share repurchase program of up to $1.5 billion, on top of $314 million remaining under a prior $1.5 billion authorization.
Illumina Inc ownership filing reports that Vanguard Capital Management beneficially owned 7,939,213 shares of Illumina common stock, representing 5.19% of the class as of 03/31/2026. The filing shows sole voting power for 1,344,377 shares and sole dispositive power for 7,939,213 shares. The report is signed on 04/30/2026 by Ashley Grim.